{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:13:27Z","timestamp":1762460007317,"version":"build-2065373602"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.msard.2021.103057","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:01:31Z","timestamp":1622505691000},"page":"103057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Can rheumatologists stop causing demyelinating disease?"],"prefix":"10.1016","volume":"53","author":[{"given":"David","family":"Baker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0513-0448","authenticated-orcid":false,"given":"Charalambos","family":"Hadjicharalambous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharmilee","family":"Gnanapavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.msard.2021.103057_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128269","article-title":"Expansion of activated peripheral blood memory B cells in rheumatoid arthritis, impact of B cell depletion therapy, and biomarkers of response","volume":"10","author":"Adlowitz","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2021.103057_bib0044","doi-asserted-by":"crossref","first-page":"e23374","DOI":"10.1002\/jcla.23374","article-title":"Overexpression of P-glycoprotein and resistance to Imatinib in chronic myeloid leukemia patients","volume":"34","author":"Ammar","year":"2020","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.msard.2021.103057_bib0033","first-page":"1","article-title":"Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives","volume":"8","author":"Anagnostou","year":"2017","journal-title":"Blood Lymphat. Cancer"},{"key":"10.1016\/j.msard.2021.103057_bib0027","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1136\/ard.2006.055194","article-title":"No signs of immunoactivation in the cerebrospinal fluid during treatment with infliximab","volume":"65","author":"Andersson","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.msard.2021.103057_bib0066","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103057_bib0089","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1136\/annrheumdis-2018-213470","article-title":"Checkpoint inhibitor-associated immune arthritis","volume":"78","author":"Arnaud","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.msard.2021.103057_bib0025","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1080\/14740338.2020.1763299","article-title":"Concerns about the safety of anti-TNF agents when treating rheumatic diseases","volume":"19","author":"Atzeni","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.msard.2021.103057_bib0015","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/eji.1830240916","article-title":"Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins","volume":"24","author":"Baker","year":"1994","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.msard.2021.103057_bib0008","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ebiom.2017.01.042","article-title":"Schmierer K memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis","volume":"16","author":"Baker","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.msard.2021.103057_bib0009","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/brain\/awy239","article-title":"Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis","volume":"141","author":"Baker","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.msard.2021.103057_bib0078","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1212\/WNL.0b013e3181d7d651","article-title":"MN166-001 Investigators. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?","volume":"74","author":"Barkhof","year":"2010","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2021.103057_bib0061","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/1352458515623862","article-title":"MS arising during Tocilizumab therapy for rheumatoid arthritis","volume":"22","author":"Beauchemin","year":"2016","journal-title":"Mult. Scler."},{"issue":"S2","key":"10.1016\/j.msard.2021.103057_bib0087","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/HS9.0000000000000244","article-title":"Mechansism of action for different checkpoint inhibitors","volume":"3","author":"Berraondo","year":"2019","journal-title":"HemaSphere"},{"key":"10.1016\/j.msard.2021.103057_bib0077","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1177\/1352458509345903","article-title":"Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood-brain barrier disruption in multiple sclerosis","volume":"15","author":"Bielekova","year":"2009","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103057_bib0056","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1172\/JCI141772","article-title":"Baricitinib restrains the immune dysregulation in patients with severe COVID-19","volume":"130","author":"Bronte","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.msard.2021.103057_bib0097","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/ard.2008.089284","article-title":"Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis","volume":"68","author":"Canete","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.msard.2021.103057_bib0048","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1124\/jpet.109.154781","article-title":"P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib","volume":"330","author":"Chen","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.msard.2021.103057_bib0011","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.msard.2021.103057_bib0094","first-page":"430","article-title":"Ectopic lymphoid structures: powerhouse of","volume":"7","author":"Corsiero","year":"2016","journal-title":"Autoimmun. Front. Immunol."},{"key":"10.1016\/j.msard.2021.103057_bib0088","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.msard.2021.103057_bib0042","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2012-11-465039","article-title":"Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling","volume":"122","author":"de Lavallade","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.msard.2021.103057_bib0001","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis - a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2021.103057_bib0070","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2217\/nmt-2020-0046","article-title":"Satralizumab in the treatment of neuromyelitis optica spectrum disorder","volume":"11","author":"Duchow","year":"2021","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.msard.2021.103057_bib0013","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2021.103057_bib0068","article-title":"Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): a case-series and review","volume":"48","author":"Elsbernd","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103057_bib0079","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1056\/NEJMoa1803583","article-title":"Phase 2 trial of ibudilast in progressive multiple sclerosis","volume":"379","author":"Fox","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103057_bib0100","first-page":"2290","article-title":"Re-examining the role of TNF in MS","volume":"9","author":"Fresegna","year":"2020","journal-title":"Pathog. Ther. Cells"},{"key":"10.1016\/j.msard.2021.103057_bib0080","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1001\/archneur.1996.00550100018004","article-title":"A pilot study of pentoxifylline in multiple sclerosis","volume":"53","author":"Friedman","year":"1996","journal-title":"Arch. Neurol."},{"issue":"1-2","key":"10.1016\/j.msard.2021.103057_bib0074","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0165-5728(98)00251-3","article-title":"Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats","volume":"95","author":"Fujimoto","year":"1999","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2021.103057_bib0073","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1073\/pnas.92.8.3601","article-title":"Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor","volume":"92","author":"Genain","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.msard.2021.103057_bib0090","article-title":"Checkpoint inhibitor-associated arthritis: a systematic review of case reports and case series","author":"Ghosh","year":"2020","journal-title":"J. Clin. Rheumatol."},{"issue":"Suppl 1","key":"10.1016\/j.msard.2021.103057_bib0002","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","article-title":"Vollmer T Brain health: time matters in multiple sclerosis","volume":"9","author":"Giovannoni","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2021.103057_bib0054","doi-asserted-by":"crossref","first-page":"e27446","DOI":"10.1002\/pbc.27446","article-title":"Toxoplasmosis and secondary Guillain-Barr\u00e9 associated with ruxolitinib as graft-versus-host disease treatment","volume":"66","author":"Gonzalez Vicent","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.msard.2021.103057_bib0020","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nature11307","article-title":"TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis","volume":"488","author":"Gregory","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.msard.2021.103057_bib0050","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/JIR.S219586","article-title":"JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data","volume":"13","author":"Harrington","year":"2020","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.msard.2021.103057_bib0012","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"OPERA I and OPERA II clinical investigators. Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103057_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101460","article-title":"Efficacy of tocilizumab for fulminant multiple sclerosis with a tumefactive cervical lesion: a 12-year-old boy","volume":"37","author":"Hoshino","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103057_bib0065","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.27221","article-title":"Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study","volume":"62","author":"Illei","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"19","key":"10.1016\/j.msard.2021.103057_bib0041","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.2169\/internalmedicine.4824-20","article-title":"Dasatinib-induced reversible demyelinating peripheral neuropathy and successful conversion to nilotinib in chronic myelogenous leukemia","volume":"59","author":"Inoue","year":"2020","journal-title":"Intern. Med."},{"key":"10.1016\/j.msard.2021.103057_bib0040","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s12185-017-2339-5","article-title":"Dasatinib-associated reversible demyelinating peripheral polyneuropathy in a case of chronic myeloid leukemia","volume":"107","author":"Ishida","year":"2018","journal-title":"Int. J. Hematol."},{"issue":"15 Suppl","key":"10.1016\/j.msard.2021.103057_bib0039","article-title":"Nilotinib-associated demyelinating disease (p2.2-093)","volume":"92","author":"Judge","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103057_bib0085","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3389\/fcell.2019.00313","article-title":"Neuroinflammation as a factor of neurodegenerative disease: thalidomide analogs as treatments","volume":"7","author":"Jung","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.msard.2021.103057_bib0017","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11910-017-0742-1","article-title":"CNS demyelination with TNF-alpha Blockers","volume":"17","author":"Kemanetzoglou","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.msard.2021.103057_bib0028","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jns.2008.05.002","article-title":"Effect of infliximab in progressive neuro-Beh\u00e7et's syndrome","volume":"272","author":"Kikuchi","year":"2008","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2021.103057_bib0005","first-page":"79","article-title":"Wiendl H the trials and errors in MS therapy","volume":"15","author":"Kleinschnitz","year":"2008","journal-title":"Int. MS J."},{"key":"10.1016\/j.msard.2021.103057_bib0062","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1177\/1352458516643395","volume":"22","author":"Kleiter","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103057_bib0029","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3904\/kjim.2018.364","article-title":"Effect of biologics in the level of cytokines in the synovial fluid of patients with ankylosing spondylitis","volume":"35","author":"Koo","year":"2020","journal-title":"Korean J. Intern. Med."},{"key":"10.1016\/j.msard.2021.103057_bib0076","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.expneurol.2013.03.026","article-title":"The phosphodiesterase-4 inhibitor rolipram protects from ischemic stroke in mice by reducing blood-brain-barrier damage, inflammation and thrombosis","volume":"247","author":"Kraft","year":"2013","journal-title":"Exp. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2021.103057_bib0053","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jaci.2015.12.1318","article-title":"Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study","volume":"137","author":"Krueger","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.msard.2021.103057_bib0018","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1177\/1352458519828601","article-title":"Iatrogenic CNS demyelination in the era of modern biologics","volume":"25","author":"Kumar","year":"2019","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2021.103057_bib0004","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3390\/cells9020482","article-title":"Helper cells: the modulators of inflammation in multiple sclerosis","volume":"9","author":"Kunkl","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.msard.2021.103057_bib0023","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.msard.2021.103057_bib0021","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/ar2809","article-title":"Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis","volume":"11","author":"Leandro","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.msard.2021.103057_bib0075","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1517\/13543784.16.7.935","article-title":"Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes","volume":"16","author":"Ledeboer","year":"2007","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.msard.2021.103057_bib0095","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/brain\/awm038","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology","volume":"130","author":"Magliozzi","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.msard.2021.103057_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102568","article-title":"CNS demyelination during tofacitinib therapy: first report","volume":"46","author":"Massoud","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103057_bib0084","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1093\/rheumatology\/kez204","article-title":"Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis","volume":"58","author":"Mavropoulos","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.msard.2021.103057_bib0063","first-page":"305","article-title":"Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling","volume":"1","author":"Mizwicki","year":"2012","journal-title":"Am. J. Neurodegener. Dis."},{"key":"10.1016\/j.msard.2021.103057_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102647","article-title":"The role of TH17 cells in multiple sclerosis: therapeutic implications","volume":"19","author":"Moser","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2021.103057_bib0083","article-title":"Effects of ibudilast on MRI measures in the phase 2 SPRINT-MS study","author":"Naismith","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103057_bib0024","doi-asserted-by":"crossref","first-page":"e845","DOI":"10.1212\/NXI.0000000000000845","article-title":"Tailoring B cell depletion therapy in MS according to memory B cell monitoring","volume":"7","author":"Novi","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103057_bib0101","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1038\/s41467-019-13616-1","article-title":"Small molecules that inhibit TNF signalling by stabilising an asymmetric form of the trimer","volume":"10","author":"O'Connell","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.msard.2021.103057_bib0091","doi-asserted-by":"crossref","first-page":"rky001","DOI":"10.1093\/rap\/rky001","article-title":"Successful use of adalimumab in immune checkpoint inhibitor-associated inflammatory arthritis","volume":"2","author":"Oke","year":"2018","journal-title":"Rheumatol. Adv. Pract."},{"key":"10.1016\/j.msard.2021.103057_bib0086","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.538695","article-title":"Central nervous system demyelination associated with immune checkpoint inhibitors: review of the literature","volume":"11","author":"Oliveira","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2021.103057_bib0026","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3389\/fnagi.2019.00373","article-title":"Blood-brain barrier and delivery of protein and gene therapeutics to brain","volume":"11","author":"Pardridge","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.msard.2021.103057_bib0032","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jbspin.2010.03.014","article-title":"Imatinib mesylate induces clinical remission in rheumatoid arthritis","volume":"77","author":"Pereira","year":"2010","journal-title":"Jt. Bone Spine"},{"key":"10.1016\/j.msard.2021.103057_bib0006","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1080\/14737175.2016.1176531","article-title":"Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010\u20132015","volume":"16","author":"Pfeuffer","year":"2016","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.msard.2021.103057_bib0047","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib crosses the blood\u2013brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.msard.2021.103057_bib0030","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1093\/brain\/123.10.2005","article-title":"Fontana A TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease","volume":"123","author":"Probert","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.msard.2021.103057_bib0102","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.neuroscience.2015.06.038","article-title":"TNF and its receptors in the CNS: the essential, the desirable and the deleterious effects","volume":"302","author":"Probert","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.msard.2021.103057_bib0096","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.msard.2018.07.030","article-title":"Oligoclonal bands in multiple sclerosis; Functional significance and therapeutic implications. Does the specificity matter?","volume":"25","author":"Pryce","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103057_bib0099","first-page":"179","article-title":"Plasma cells as a marker predicting the outcome of anti-TNF therapy","volume":"15","author":"R\u016f\u017ei\u010dkov\u00e1","year":"2007","journal-title":"\u010ces. Revmatol."},{"key":"10.1016\/j.msard.2021.103057_bib0036","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1080\/10428194.2019.1633635","article-title":"Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series","volume":"60","author":"Rafei","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.msard.2021.103057_bib0045","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/637059","article-title":"Efficacy and pharmacologic data of second-generation tyrosine kinase inhibitor nilotinib in BCR-ABL-positive leukemia patients with central nervous system relapse after allogeneic stem cell transplantation","volume":"2014","author":"Reinwald","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.msard.2021.103057_bib0038","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2016-315106.154","article-title":"CNS demyelination in patients on nilotinib treatment for CML","volume":"87","author":"Rekhi","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiat."},{"issue":"7","key":"10.1016\/j.msard.2021.103057_bib0059","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1007\/s00415-020-09866-5","article-title":"CNS penetration of potential anti-COVID-19 drugs","volume":"267","author":"Richardson","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.103057_bib0081","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0165-5728(95)00176-X","article-title":"Poser S pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis","volume":"64","author":"Rieckmann","year":"1996","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2021.103057_bib0057","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2016.10.005","article-title":"Impact of tofacitinib treatment on human B-cells in vitro and in vivo","volume":"77","author":"Rizzi","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.msard.2021.103057_bib0082","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1365-2125.2008.03270.x","article-title":"Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses","volume":"66","author":"Rolan","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.msard.2021.103057_bib0007","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40259-020-00435-w","article-title":"Meuth SG failed, interrupted, or inconclusive trials on immunomodulatory treatment strategies in multiple sclerosis: update 2015\u20132020","volume":"34","author":"Rolfes","year":"2020","journal-title":"BioDrugs"},{"key":"10.1016\/j.msard.2021.103057_bib0064","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/art.30242","article-title":"In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment","volume":"63","author":"Roll","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.msard.2021.103057_bib0037","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/1352458519892914","article-title":"CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: a report of two cases","volume":"26","author":"Rotstein","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103057_bib0014","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1084\/jem.172.4.1193","article-title":"An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis","volume":"172","author":"Ruddle","year":"1990","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.msard.2021.103057_bib0098","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/annrheumdis-2011-201270","article-title":"Anti-TNF treatment blocks the induction of T cell-dependent humoral responses","volume":"72","author":"Salinas","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.msard.2021.103057_bib0060","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","article-title":"Tocilizumab: a review in rheumatoid arthritis","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.msard.2021.103057_bib0010","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.msard.2017.03.013","article-title":"Depletion of CD20 B cells fails to inhibit relapsing mouse experimental autoimmune encephalomyelitis","volume":"14","author":"Sefia","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103057_bib0092","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1200\/JOP.19.00438","article-title":"Optic neuritis related to atezolizumab treatment in a patient with metastatic non-small-cell lung cancer","volume":"16","author":"Sengul Samanci","year":"2020","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.msard.2021.103057_bib0051","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3899\/jrheum.171361","article-title":"Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment","volume":"46","author":"Smolen","year":"2019","journal-title":"J. Rheumatol."},{"issue":"3","key":"10.1016\/j.msard.2021.103057_bib0072","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nm0395-244","article-title":"The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis","volume":"1","author":"Sommer","year":"1995","journal-title":"Nat. Med."},{"key":"10.1016\/j.msard.2021.103057_bib0049","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/blood.V116.21.1807.1807","article-title":"Dasatinib cerebrospinal fluid concentration and plasma pharmacokinetics: potential for central nervous system prophylaxis in philadelphia chromosome-positive leukemia","volume":"116","author":"Takahashi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.msard.2021.103057_bib0093","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.4049\/jimmunol.167.8.4710","article-title":"T cell activation in rheumatoid synovium is B cell dependent","volume":"167","author":"Takemura","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.msard.2021.103057_bib0058","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/art.40680","article-title":"Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis","volume":"70","author":"Tanaka","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.msard.2021.103057_bib0019","doi-asserted-by":"crossref","first-page":"e992","DOI":"10.1212\/NXI.0000000000000992","article-title":"Demyelinating events following initiation of anti-TNF\u03b1 therapy in the British society for rheumatology biologics registry in rheumatoid arthritis","volume":"8","author":"Taylor","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103057_bib0046","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/jamaneurol.2020.4725","article-title":"Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial","volume":"78","author":"Simuni","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2021.103057_bib0055","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1177\/1078155219878774","article-title":"Ruxolitinib for the treatment of lymphoma-associated hemophagocytic lymphohistiocytosis: a cautionary tale","volume":"26","author":"Trantham","year":"2020","journal-title":"Oncol. Pharm. Pract."},{"key":"10.1016\/j.msard.2021.103057_bib0016","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2","volume":"47","author":"van Oosten","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103057_bib0031","first-page":"26","article-title":"Resolution of rheumatoid arthritis symptoms with imatinib mesylate","volume":"15","author":"Vernon","year":"2009","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.msard.2021.103057_bib0034","doi-asserted-by":"crossref","first-page":"13622","DOI":"10.1073\/pnas.0501758102","article-title":"The kinase inhibitor imatinib mesylate inhibits TNF alpha production in vitro and prevents TNF-dependent acute hepatic inflammation","volume":"102","author":"Wolf","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.msard.2021.103057_bib0043","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1182\/blood-2002-10-3059","article-title":"The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr\/Abl-induced leukemia","volume":"101","author":"Wolff","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.msard.2021.103057_bib0069","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of Satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103057_bib0035","first-page":"54","article-title":"Serum level of TNF-alpha in patients with chronic myeloid leukemia on Imatinib therapy","volume":"22","author":"Zbaar","year":"2017","journal-title":"Tikr. Med. J."},{"key":"10.1016\/j.msard.2021.103057_bib0067","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821003242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821003242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:56:09Z","timestamp":1761900969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821003242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":102,"alternative-id":["S2211034821003242"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103057","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can rheumatologists stop causing demyelinating disease?","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103057"}}